{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:12:21Z","timestamp":1783743141374,"version":"3.55.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012639","name":"METAvivor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012639","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Whether outcomes of germline BRCA1\/2 (gBRCA1\/2)-associated breast cancer differ compared with sporadic tumors is controversial. We explored the impact of gBRCA1\/2 pathogenic variant (PV) status beyond established prognostic features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted 2 retrospective, matched cohort studies comparing gBRCA1\/2 PV carriers and noncarriers with HER2-negative, stage I-III breast cancer (Clinical Outcomes Quality Database [COQD] cohort: 185 carriers, 555 noncarriers; Young Women\u2019s Breast Cancer Study [YWS] cohort: 113 carriers, 226 noncarriers). Matching factors were age, stage, hormone receptor status, and year of diagnosis. Clinicopathological features, treatments, and survival outcomes were compared between carriers and noncarriers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most patients in COQD had stage I-II disease (87.2%), and more carriers than noncarriers had genetic testing before diagnosis (33% vs 5.6%, P\u2009&amp;lt;\u2009.001). In YWS, 22.7% of patients had stage III tumors, and few were tested before diagnosis (14.8% of carriers vs 1.7% of noncarriers; P\u2009&amp;lt;\u2009.001). Carriers in COQD received chemotherapy more often than noncarriers (81.1 vs 67.0%, P\u2009&amp;lt;\u2009.001), including platinum (P\u2009=\u2009.010); the proportion was similar for carriers and noncarriers in YWS. After adjusting for chemotherapy, relapse-free survival was longer in carriers than noncarriers in COQD (adjusted hazard ratio = 0.48 [95% CI\u2009=\u20090.26 to 0.87], P\u2009=\u2009.016), and a favorable trend was observed for other survival outcomes in both cohorts. Triple-negative tumors appeared to drive the differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We observed a trend toward improved outcomes in gBRCA1\/2 PV carriers compared with noncarriers. These findings suggest that carriers should not receive more aggressive treatment solely based on their germline mutation status. Prospective clinical trials in this population are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jncics\/pkag055","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T11:41:31Z","timestamp":1779536491000},"source":"Crossref","is-referenced-by-count":0,"title":["Outcomes and treatment patterns in germline\n                    <i>BRCA1\/2<\/i>\n                    carriers from two matched cohort studies"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5284-9944","authenticated-orcid":false,"given":"Stefania","family":"Morganti","sequence":"first","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center , Boston, MA,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA,","place":["United States"]},{"name":"Broad Institute of MIT and Harvard , Cambridge, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se E","family":"Kim","sequence":"additional","affiliation":[{"name":"Data Science, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6388-5123","authenticated-orcid":false,"given":"Qingchun","family":"Jin","sequence":"additional","affiliation":[{"name":"Data Science, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1436-369X","authenticated-orcid":false,"given":"Jaeyoon","family":"Cha","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline E","family":"Zeigler","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1174-1541","authenticated-orcid":false,"given":"Alexandra B","family":"Newman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0386-5223","authenticated-orcid":false,"given":"Gregory J","family":"Kirkner","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1572-4895","authenticated-orcid":false,"given":"Craig","family":"Snow","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2294-813X","authenticated-orcid":false,"given":"Yue","family":"Zheng","sequence":"additional","affiliation":[{"name":"Data Science, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Vincuilla","sequence":"additional","affiliation":[{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center , Boston, MA,","place":["United States"]},{"name":"Division of Breast Surgery, Department of Surgery, Brigham and Women\u2019s Hospital , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2866-7022","authenticated-orcid":false,"given":"Tonia","family":"Parker","sequence":"additional","affiliation":[{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center , Boston, MA,","place":["United States"]},{"name":"Division of Breast Surgery, Department of Surgery, Brigham and Women\u2019s Hospital , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4798-1365","authenticated-orcid":false,"given":"Ryan M","family":"Buehler","sequence":"additional","affiliation":[{"name":"Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7969-0603","authenticated-orcid":false,"given":"Brittany L","family":"Bychkovsky","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center , Boston, MA,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA,","place":["United States"]},{"name":"Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6791-2977","authenticated-orcid":false,"given":"Kate E","family":"Dibble","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center , Boston, MA,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2030-9200","authenticated-orcid":false,"given":"Tal","family":"Sella","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center , Boston, MA,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6298-332X","authenticated-orcid":false,"given":"Kathryn J","family":"Ruddy","sequence":"additional","affiliation":[{"name":"Mayo Clinic Department of Oncology, , Rochester, MN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshana M","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center , Boston, MA,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C","family":"Collins","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine\/New York Presbyterian Hospital Department of Pathology and Laboratory Medicine, , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7138-6404","authenticated-orcid":false,"given":"Jeffrey","family":"Peppercorn","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA,","place":["United States"]},{"name":"Massachusetts General Hospital Division of Hematology\/Oncology, , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Schapira","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute Division of Medical Oncology, Department of Medicine, , Palo Alto, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-7524","authenticated-orcid":false,"given":"Virginia F","family":"Borges","sequence":"additional","affiliation":[{"name":"University of Colorado Division of Medical Oncology, Department of Medicine, , Denver, CO,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7574-2729","authenticated-orcid":false,"given":"Yaileen D","family":"Guzman-Arocho","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center Department of Pathology, , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8136-2908","authenticated-orcid":false,"given":"Steven E","family":"Come","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA,","place":["United States"]},{"name":"Massachusetts General Hospital Division of Hematology\/Oncology, , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Warner","sequence":"additional","affiliation":[{"name":"Sunnybrook Health Sciences Centre Odette Cancer Centre, , Toronto, Ontario,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3664-5727","authenticated-orcid":false,"given":"Philip D","family":"Poorvu","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center , Boston, MA,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[{"name":"Ente Ospedaliero Ospedali Galliera Medical Oncology Unit, , Genova,","place":["Italy"]},{"name":"Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova , Genoa,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS , Milan,","place":["Italy"]},{"name":"Department of Oncology and Haemato-Oncology, University of Milano , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa E","family":"Hughes","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9762-8536","authenticated-orcid":false,"given":"Elizabeth A","family":"Mittendorf","sequence":"additional","affiliation":[{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center , Boston, MA,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA,","place":["United States"]},{"name":"Division of Breast Surgery, Department of Surgery, Brigham and Women\u2019s Hospital , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3602-2351","authenticated-orcid":false,"given":"Tari A","family":"King","sequence":"additional","affiliation":[{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center , Boston, MA,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA,","place":["United States"]},{"name":"Division of Breast Surgery, Department of Surgery, Brigham and Women\u2019s Hospital , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2263-5413","authenticated-orcid":false,"given":"Nancy U","family":"Lin","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center , Boston, MA,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-3982","authenticated-orcid":false,"given":"Judy E","family":"Garber","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center , Boston, MA,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA,","place":["United States"]},{"name":"Department of Medicine, Brigham and Women\u2019s Hospital , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6088-167X","authenticated-orcid":false,"given":"Nabihah","family":"Tayob","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA,","place":["United States"]},{"name":"Broad Institute of MIT and Harvard , Cambridge, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-8671","authenticated-orcid":false,"given":"Sara M","family":"Tolaney","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center , Boston, MA,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4722-4824","authenticated-orcid":false,"given":"Ann H","family":"Partridge","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center , Boston, MA,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6615-7076","authenticated-orcid":false,"given":"Filipa","family":"Lynce","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center , Boston, MA,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"2026071023311488800_pkag055-B1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes: association analysis in more than 113,000 women","volume":"384","author":"Dorling","year":"2021","journal-title":"N Engl J Med"},{"key":"2026071023311488800_pkag055-B2","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","article-title":"Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer","volume":"26","author":"Atchley","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026071023311488800_pkag055-B3","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1038\/sj.onc.1209876","article-title":"Basal-like breast cancer and the BRCA1 phenotype","volume":"25","author":"Turner","year":"2006","journal-title":"Oncogene"},{"key":"2026071023311488800_pkag055-B4","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1200\/JCO-24-01334","article-title":"Clinical behavior of breast cancer in young BRCA carriers and prediagnostic awareness of germline BRCA status","volume":"43","author":"Lambertini","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026071023311488800_pkag055-B5","doi-asserted-by":"crossref","first-page":"e0120189","DOI":"10.1371\/journal.pone.0120189","article-title":"Worse breast cancer prognosis of BRCA1\/BRCA2 mutation carriers: what\u2019s the evidence? A systematic review with meta-analysis","volume":"10","author":"van den Broek","year":"2015","journal-title":"PLoS One"},{"key":"2026071023311488800_pkag055-B6","doi-asserted-by":"crossref","first-page":"e4975","DOI":"10.1097\/MD.0000000000004975","article-title":"Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis","volume":"95","author":"Baretta","year":"2016","journal-title":"Medicine"},{"key":"2026071023311488800_pkag055-B7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1158\/1078-0432.CCR-14-1816","article-title":"Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis","volume":"21","author":"Zhong","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026071023311488800_pkag055-B8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","article-title":"Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study","volume":"19","author":"Copson","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026071023311488800_pkag055-B9","doi-asserted-by":"crossref","first-page":"e081157","DOI":"10.1136\/bmjopen-2023-081157","article-title":"Helping ourselves, helping others: the Young Women\u2019s Breast Cancer Study (YWS)\u2014a multisite prospective cohort study to advance the understanding of breast cancer diagnosed in women aged 40 years and younger","volume":"14","author":"Rosenberg","year":"2024","journal-title":"BMJ Open"},{"key":"2026071023311488800_pkag055-B10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"2026071023311488800_pkag055-B11","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1200\/JCO.20.03613","article-title":"Updated Standardized Definitions for Efficacy End Points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026071023311488800_pkag055-B12","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.annonc.2024.06.009","article-title":"Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers","volume":"35","author":"Arecco","year":"2024","journal-title":"Ann Oncol"},{"key":"2026071023311488800_pkag055-B13","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"2026071023311488800_pkag055-B14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"2026071023311488800_pkag055-B15","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.21.01532","article-title":"Adjuvant PARP inhibitors in patients with high-risk early-stage HER2-negative breast cancer and germline BRCA mutations: ASCO hereditary breast cancer guideline rapid recommendation update","volume":"39","author":"Tung","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026071023311488800_pkag055-B16","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.20.00299","article-title":"Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology guideline","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026071023311488800_pkag055-B17","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkac045","article-title":"Chemotherapy regimens received by women with BRCA1\/2 pathogenic variants for early stage breast cancer treatment","volume":"6","author":"Kurian","year":"2022","journal-title":"JNCI Cancer Spectr"},{"key":"2026071023311488800_pkag055-B18","doi-asserted-by":"crossref","first-page":"S322","DOI":"10.1016\/j.annonc.2025.08.759","article-title":"330P Association of type of chemotherapy with survival outcomes in young BRCA1\/2 carriers with HER2-negative early breast cancer: a secondary analysis of the BRCA BCY collaboration","volume":"36","author":"Bernstein Molho","year":"2025","journal-title":"Ann Oncol"},{"key":"2026071023311488800_pkag055-B19","doi-asserted-by":"crossref","first-page":"10510","DOI":"10.1200\/JCO.2025.43.16_suppl.10510","article-title":"Germline pathogenic variants in cancer predisposition genes and overall survival of women with breast cancer","volume":"43","author":"Yadav","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026071023311488800_pkag055-B20","doi-asserted-by":"crossref","first-page":"GS1-09","DOI":"10.1158\/1557-3265.SABCS24-GS1-09","article-title":"Abstract GS1-09: OlympiA: a phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w\/ germline BRCA1 & BRCA2 pathogenic variants & high-risk HER2-negative primary breast cancer","volume":"31(12_Supplement)","author":"Garber","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026071023311488800_pkag055-B21","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1470-2045(25)00152-4","article-title":"Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study","volume":"26","author":"Blondeaux","year":"2025","journal-title":"Lancet Oncol"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkag055\/68386884\/pkag055.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/10\/4\/pkag055\/68386884\/pkag055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/10\/4\/pkag055\/68386884\/pkag055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:31:31Z","timestamp":1783740691000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkag055\/8692939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkag055","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,5,25]]},"article-number":"pkag055"}}